Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Equity Ratio (2016 - 2025)

Cytokinetics (CYTK) has disclosed Equity Ratio for 16 consecutive years, with 0.46 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio changed N/A to 0.46 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.46, a N/A change, with the full-year FY2025 number at 0.46, changed N/A from a year prior.
  • Equity Ratio was 0.46 for Q4 2025 at Cytokinetics, down from 0.36 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.3 in Q3 2021 to a low of 0.59 in Q3 2023.
  • A 5-year average of 0.14 and a median of 0.11 in 2022 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: surged 394.08% in 2022, then tumbled 3890.04% in 2023.
  • Cytokinetics' Equity Ratio stood at 0.29 in 2021, then crashed by 136.68% to 0.11 in 2022, then crashed by 340.76% to 0.47 in 2023, then surged by 97.93% to 0.01 in 2024, then tumbled by 4680.11% to 0.46 in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Equity Ratio are 0.46 (Q4 2025), 0.36 (Q3 2025), and 0.3 (Q2 2025).